

## GLA Injectable HIV PrEP Guidance (updated 1/19/23)

### Indications for injectable PrEP

---

#### Cabotegravir (CAB) 600mg injection (Apretude) every 2 months (after initial injections at 0 and 1 month)

- Indicated for use in persons at high risk for HIV and one of the following criteria:
  - Intolerance or contraindication to Truvada or Descovy
  - CrCl <30 or multiple risk factors for significant renal dysfunction
  - Patient specific factors impacting adherence to daily oral PrEP (e.g. cognitive difficulties, gastrointestinal dysfunction, unstable housing, stigma)
  - Patient at very high risk for HIV acquisition
  - Cis-gender women ineligible for Truvada
- Not to be used in persons with noncompliance to follow-up appointments
- Drug interactions with cabotegravir: Rifamycin derivatives (rifampin, rifabutin), UTG1A1 inducers (carbamazepine, oxcarbazepine, phenobarbital, phenytoin), St. John's Wort

### Baseline laboratory tests/diagnostic procedures

---

- Documented negative HIV antigen/antibody test and HIV RNA PCR *within one week* prior to initiation
- RPR, testing for gonorrhea and Chlamydia (including rectal and pharyngeal testing as appropriate)
- HBV surface antigen, core antibody, and surface antibody
- HCV antibody testing
- Pregnancy test (women of child-bearing age)
- Screen for acute HIV symptoms. If any signs/symptoms in previous month, may:
  - Retest HIV RNA PCR in 2-4 weeks and defer PrEP
    - If detectable viral load: defer PrEP, refer to Infectious Diseases
    - If undetectable viral load **and** no signs/symptoms on day of blood draw: HIV-negative, may start PrEP

### Follow-up and monitoring (injectable PrEP)

---

#### Initial visit:

- Review labs
- Counseling on adherence, safer sexual practices, and side effects (injection site pain)
- Administer cabotegravir 600mg
- Order HIV antigen/antibody test, HIV RNA PCR, and STI testing for 1 week prior to next visit (in one month)

#### One month visit:

- Review HIV antigen/antibody, HIV RNA PCR, and STI labs
- Counseling on adherence, safer sexual practices, and side effects (injection site pain)
- Administer cabotegravir 600mg
- Order HIV antigen/antibody test, HIV RNA PCR, and STI testing for 1 week prior to next visit (in two months)

Every two months visit:

- Review HIV antigen/antibody, HIV RNA PCR, and STI labs
- Counseling on adherence, safer sexual practices, and side effects (injection site pain)
- Administer cabotegravir 600mg
- Order HIV antigen/antibody test, HIV RNA PCR, and STI testing for 1 week prior to next visit (in two months)

Missed visit:

- Contact patient and attempt to reschedule visit **within 1 week**
- If unable to reschedule visit within 7 days then prescribe oral PrEP (oral CAB or TDF/FTC or TAF/FTC if CrCl <60) for up to 2 months

### **Discontinuation of injectable PrEP**

---

COUNSELING:

- Cabotegravir levels wane slowly after the last injection (“tail” phase). This subtherapeutic drug level present risk for acquisition of drug-resistant HIV during this phase.
  - If HIV exposure/risk will continue then prescribe daily oral PrEP within 8 weeks after the last cabotegravir injection

FOLLOW-UP:

- Continue every three months follow-up visits for 12 months after discontinuation of injectable PrEP
  - At these visits screen for HIV with Ag/Ab and HIV RNA PCR

### **Scheduling**

---

We will initially manage all injectable PrEP patients in Friday AM clinic only. These patients will be managed and Sharon Garner or Feliza Calub.

Clinic name: WLA-ID PrEP Injection Clinic

Fridays: 0830, 0930, 1030 (no overbooks)

Location: 1 West